

WEST Search History

DATE: Tuesday, May 17, 2005

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L34	L33 and rabies	1
<input type="checkbox"/>	L33	6194560.pn.	1
<input type="checkbox"/>	L32	5989561.pn. and rabies	1
<input type="checkbox"/>	L31	5989561.pn.	1
<input type="checkbox"/>	L30	L28 and protection	1
<input type="checkbox"/>	L29	L28 and cross	1
<input type="checkbox"/>	L28	5843456.pn.	1
<input type="checkbox"/>	L27	5843356.pn.	1
<input type="checkbox"/>	L26	herpesvirus cross recativity	0
	<i>DB=PGPB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L25	herpesvirus cross recativity	0
<input type="checkbox"/>	L24	herpesvirus cross protection	0
<input type="checkbox"/>	L23	rabies cross protection	0
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L22	rabies cross protection	0
	<i>DB=DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L21	rabies cross protection	0
<input type="checkbox"/>	L20	rabies antigenic cross reactivity	0
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L19	rabies antigenic cross reactivity	0
	<i>DB=PGPB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L18	rabies antigenic cross reactivity	0
<input type="checkbox"/>	L17	rabies antigenic cross activity	0
<input type="checkbox"/>	L16	rabies overlapping activity	0
<input type="checkbox"/>	L15	rabies cross reactivity	0
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L14	rabies cross reactivity	0
	<i>DB=DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L13	rabies cross reactivity	0
<input type="checkbox"/>	L12	rabies cross reactivity and herpesvirus	0
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		

<input type="checkbox"/>	L11	US-4680176-A.did.	1
<input type="checkbox"/>	L10	US-4680176-A.did.	1
		<i>DB=DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L9	rabies and herpesvirus	23
		<i>DB=USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L8	rabies and herpesvirus.clm.	54
<input type="checkbox"/>	L7	4584194.pn.	1
<input type="checkbox"/>	L6	4351827.pn.	1
<input type="checkbox"/>	L5	4341762.pn.	1
<input type="checkbox"/>	L4	0206940.pn.	1
<input type="checkbox"/>	L3	4657761.pn.	1
<input type="checkbox"/>	L2	6174916.pn.	1
<input type="checkbox"/>	L1	4415590.pn.	1

END OF SEARCH HISTORY

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, May 17, 2005

Hide?	Set Name	Query	Hit Count
		<i>DB=USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L10	herpes cross reacting rabies	0
<input type="checkbox"/>	L9	rabies cross reacting herpes	0
<input type="checkbox"/>	L8	L6 and rabies	12
<input type="checkbox"/>	L7	L6 and herpesvirus	9
<input type="checkbox"/>	L6	beta propriolactone	112
		<i>DB=JPAB; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L5	IMOVAX	0
		<i>DB=EPAB; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L4	IMOVAX	0
		<i>DB=DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L3	IMOVAX	0
		<i>DB=PGPB; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L2	IMOVAX	3
		<i>DB=USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L1	IMOVAX	5

END OF SEARCH HISTORY

TI Polynucleotide vaccine formula against canine pathologies
IN Audonnet, Jean-Christophe, Lyons, France
Bouchardon, Annabelle, Lyons, France
Riviere, Michel, Ecully, France
PA Merial, Lyons, France (non-U.S. corporation)
PI US 6228846 B1 20010508
AI US 1999-232477 19990115 (9)
RLI Continuation-in-part of Ser. No. WO 1997-FR1316, filed on 15 Jul 1997
PRAI FR 1996-9401 19960719
DT Utility
FS Granted
LN.CNT 888
INCL INCLM: 514/044.000
INCLS: 435/320.100; 536/023.720; 536/023.700
NCL NCLM: 514/044.000
NCLS: 435/320.100; 536/023.700; 536/023.720
IC [7]
ICM: A61K031-70
EXF 514/44; 424/233.1; 435/320.1; 435/23.7; 536/23.72
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 13 USPATFULL on STN
AN 2001:29710 USPATFULL
TI Oral immunization with transgenic plants
IN Arntzen, Charles J., Ithaca, NY, United States
Mason, Hugh S., Ithaca, NY, United States
Haq, Tariq A., San Antonio, TX, United States
PA Texas A & M University System, College Station, TX, United States (U.S. corporation)
PI US 6194560 B1 20010227
AI US 1998-191852 19981112 (9)
RLI Division of Ser. No. US 817906, now abandoned Continuation-in-part of Ser. No. US 1994-328716, filed on 24 Oct 1994, now abandoned
DT Utility
FS Granted
LN.CNT 2819
INCL INCLM: 536/023.700
INCLS: 800/278.000; 800/288.000; 800/295.000; 530/350.000; 435/069.100; 435/069.300; 435/410.000; 435/419.000; 435/252.300; 435/252.330; 435/252.800; 435/320.100; 424/184.100; 424/185.100; 424/186.100; 424/190.100; 424/192.100; 424/193.100; 424/204.100; 424/227.100; 424/236.100; 424/241.100; 424/282.100; 536/023.100
NCL NCLM: 536/023.700
NCLS: 424/184.100; 424/185.100; 424/186.100; 424/190.100; 424/192.100; 424/193.100; 424/204.100; 424/227.100; 424/236.100; 424/241.100; 424/282.100; 435/069.100; 435/069.300; 435/252.300; 435/252.330; 435/252.800; 435/320.100; 435/410.000; 435/419.000; 530/350.000; 536/023.100; 800/278.000; 800/288.000; 800/295.000
IC [7]
ICM: A61K039-108
ICS: C07H021-04; C07K014-245; C12N005-14
EXF 536/23.1; 536/23.7; 800/278; 800/288; 800/295; 530/350; 435/69.1; 435/69.3; 435/410; 435/419; 435/252.3; 435/252.33; 435/252.8; 435/320.1; 424/184.1; 424/185.1; 424/186.1; 424/190.1; 424/192.1; 424/193.1; 424/204.1; 424/227.1; 424/236.1; 424/241.1; 424/282.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 13 USPATFULL on STN
AN 1999:150664 USPATFULL
TI Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
IN Paoletti, Enzo, Delmar, NY, United States
Fischer, Laurent, Albany, NY, United States
Legros, Francois-Xavier, Oullins, France
PA Virogenetics Corporation, Troy, NY, United States (U.S. corporation)
PI US 5989561 19991123
AI US 1995-471025 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1993-105483, filed on 13 Aug 1993,

now patented, Pat. No. US 5494807 And Ser. No. US 1993-36217, filed on 24 Mar 1993, now patented, Pat. No. US 5364773, issued on 15 Nov 1994 which is a continuation of Ser. No. US 1991-666056, filed on 7 Mar 1991, now abandoned, said Ser. No. US 105483 which is a continuation of Ser. No. US 1992-847951, filed on 6 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-713967, filed on 11 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 666056

DT Utility
FS Granted

LN.CNT 3738

INCL INCLM: 424/199.100
INCLS: 424/204.100; 435/235.100; 435/320.100; 435/325.000; 435/069.100;
536/024.310; 536/024.330; 536/023.720

NCL NCLM: 424/199.100
NCLS: 424/204.100; 435/069.100; 435/235.100; 435/320.100; 435/325.000;
536/023.720; 536/024.310; 536/024.330

IC [6]
ICM: A61K039-285
ICS: C12N015-80; C12N007-01

EXF 424/199.1; 424/204.1; 435/235.1; 435/320.1; 435/325; 435/69.1;
536/24.31; 536/23.72; 536/24.33

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 13 USPATFULL on STN

AN 1999:72572 USPATFULL

TI DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof

IN Webster, Robert, Memphis, TN, United States

PA St. Jude Children's Research Hospital, Memphis, TN, United States (U.S. corporation)

PI US 5916879 19990629

AI US 1996-747286 19961112 (8)

DT Utility

FS Granted

LN.CNT 1891

INCL INCLM: 514/044.000
INCLS: 435/459.000; 435/320.100; 536/023.720; 424/209.100; 424/210.100;
424/816.000

NCL NCLM: 514/044.000
NCLS: 424/209.100; 424/210.100; 424/816.000; 435/320.100; 435/459.000;
536/023.720

IC [6]
ICM: A61K048-00
ICS: C12N015-87; C12N015-44

EXF 536/23.72; 514/44; 424/209.1; 424/816; 424/199.1; 424/210.1; 435/320.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 13 USPATFULL on STN

AN 1998:150475 USPATFULL

TI Alvac poxvirus-**rabies** compositions and combination compositions and uses

IN Paoletti, Enzo, Delmar, NY, United States

Maki, Joanne, Colbert, GA, United States

PA Virogenetics Corporation, Troy, NY, United States (U.S. corporation)

PI US 5843456 19981201

AI US 1995-486969 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1993-105483, filed on 13 Aug 1993, now patented, Pat. No. US 5494807 which is a continuation of Ser. No. US 1992-847951, filed on 6 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-713967, filed on 11 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-666056, filed on 7 Mar 1991, now abandoned which is a continuation of Ser. No. US 1993-36217, filed on 24 Mar 1993, now patented, Pat. No. US 5364773, issued on 15 Nov 1994

DT Utility
FS Granted

LN.CNT 7179

INCL INCLM: 424/199.100

INCLS: 424/204.100; 424/201.100; 424/202.100; 424/205.100; 424/218.100;
424/224.100; 435/320.100; 435/069.300; 435/172.300; 435/235.100;
435/252.300; 530/350.000; 530/826.000; 514/002.000
NCL NCLM: 424/199.100
NCLS: 424/201.100; 424/202.100; 424/204.100; 424/205.100; 424/218.100;
424/224.100; 435/069.300; 435/235.100; 435/252.300; 435/320.100;
514/002.000; 530/350.000; 530/826.000
IC [6]
ICM: A61K039-275
ICS: A61K039-295; A61K039-205

=> d 19 1-64 ti

- L9 ANSWER 1 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Assessment of potency of canine vaccines during their shelf life.
- L9 ANSWER 2 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Molecular methods for diagnosis of viral encephalitis.
- L9 ANSWER 3 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Host-dependent type 1 cytokine responses driven by inactivated viruses may fail to default in the absence of IL-1 2 or IFN-alpha/beta.
- L9 ANSWER 4 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Human immunodeficiency virus transmitted through sheep brain anti-
rabies vaccination.
- L9 ANSWER 5 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Bovine **herpesvirus** type 5 (BHV-5) in a calf with **rabies**
- L9 ANSWER 6 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Cerebellar loops pith motor cortex and prefrontal cortex of a nonhuman primate.
- L9 ANSWER 7 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Diagnostic immunohistochemistry of equine and avian infectious diseases.
- L9 ANSWER 8 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Infection as a cause of multiple sclerosis: Theories abound because no one knows the answers yet.
- L9 ANSWER 9 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Detection of bovine **herpesvirus** type 5 (BoHV-5) in cattle in Southeast Brazil.
Original Title: Deteccao de **herpesvirus** bovino 5 (BoHV-5) em bovinos do Sudeste Brasileiro.
- L9 ANSWER 10 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Interaction of the poliovirus receptor CD155 with the dynein light chain Tctex-1 and its implication for poliovirus pathogenesis.
- L9 ANSWER 11 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI DNA immunization and central nervous system viral infection.
- L9 ANSWER 12 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Programmed cell death in virus infections of the nervous system.
- L9 ANSWER 13 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Canine **herpesvirus** based recombinant live vaccine, in particular against canine distemper, **rabies** or the parainfluenza 2 virus.
- L9 ANSWER 14 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Viral diseases of northern ungulates.
- L9 ANSWER 15 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Passive immunity in prevention and treatment of infectious diseases.
- L9 ANSWER 16 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Serologic survey of selected viral agents in recently captured wild North American river otters (*Lontra canadensis*).

L9 ANSWER 17 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Diseases of the central nervous system in cattle of southern Brazil.

L9 ANSWER 18 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Endogenous retroviruses: Are they the cause of multiple sclerosis?.

L9 ANSWER 19 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI New approaches to the development of virus vaccines for veterinary use.

L9 ANSWER 20 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Construction of canine **herpesvirus** vector expressing foreign
genes using a lacZ-TK gene cassette as a double selectional marker.

L9 ANSWER 21 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Feline vaccine guidelines.

L9 ANSWER 22 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Biological and immunogenic properties of **rabies** virus
glycoprotein expressed by canine **herpesvirus** vector.

L9 ANSWER 23 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Emerging viruses.

L9 ANSWER 24 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Immunopathogenesis of virus diseases affecting the central nervous system.

L9 ANSWER 25 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Protein-glycosaminoglycan interactions: Infectiological aspects.

L9 ANSWER 26 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Viral encephalitides.

L9 ANSWER 27 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Guidelines for vaccination of horses.

L9 ANSWER 28 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Effects of incidental infections and immune activation on disease
progression in experimentally feline immunodeficiency virus-infected cats.

L9 ANSWER 29 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Resistance of mice vaccinated with **rabies** virus internal
structural proteins to lethal infection.

L9 ANSWER 30 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI Diseases and parasites of red foxes, gray foxes, and coyotes from
commercial sources selling to fox-chasing enclosures.

L9 ANSWER 31 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI PRINCIPLES AND PRACTICE OF CLINICAL VIROLOGY 2ND EDITION.

L9 ANSWER 32 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI THERAPY OF VIRAL INFECTIONS OF THE CENTRAL NERVOUS SYSTEM.

L9 ANSWER 33 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI PENETRATION OF THE NERVOUS SYSTEM OF SUCKLING MICE BY MAMMALIAN
REOVIRUSES.

L9 ANSWER 34 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI A CASE REPORT ENCEPHALITIS IN LIONS PATHOLOGICAL AND VIROLOGICAL FINDINGS.

L9 ANSWER 35 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI USE OF GENETIC ENGINEERING METHODS IN VIRAL VACCINE PRODUCTION.

L9 ANSWER 36 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI SEROLOGIC SURVEY OF VIRAL ANTIBODIES IN THE PERUVIAN ALPACA LAMA-PACOS.

L9 ANSWER 37 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI PERSISTENT VIRAL INFECTION THE CARRIER STATE.

L9 ANSWER 38 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI DIAGNOSIS OF FELINE VIRAL INFECTION.

L9 ANSWER 39 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI SLOW LATENT CHRONIC OR RECURRENT VIRAL INFECTIONS OF THE NERVOUS SYSTEM IN
MAN.

L9 ANSWER 40 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI CELLULAR IMMUNITY IN **HERPESVIRUS** THAI HEMORRHAGIC FEVER AND
OTHER CELLULAR INFECTIONS WITH EMPHASIS ON ISOPRINOSINE.

L9 ANSWER 41 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI VIRAL INFECTIONS OF THE NERVOUS SYSTEM.

L9 ANSWER 42 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI RAPID VIRUS DIAGNOSIS APPLICATION OF IMMUNO FLUORESCENCE 2ND EDITION.

L9 ANSWER 43 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI SEARCH FOR ANTI VIRAL AGENTS.

L9 ANSWER 44 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI PRIMARY SCREENING OF VIRAL INHIBITORS IN TISSUE CULTURE.

L9 ANSWER 45 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI INACTIVATION OF A TURKEY **HERPESVIRUS** BY UV LIGHT.

L9 ANSWER 46 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI CANINE AND FELINE IMMUNIZATION.

L9 ANSWER 47 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI THE COMPARISON OF VIRAL ANTIBODY TITERS OF ACID PRECIPITATED AND
NONPRECIPITATED MOUSE ASCITIC FLUIDS.

L9 ANSWER 48 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI INDUCTION OF INTERFERON IN-VIVO BY POLY NUCLEOTIDES.

L9 ANSWER 49 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI SENSITIVITY OF VARIOUS PRIMATE CELLS AND ANIMAL VIRUSES TO THE ANTI VIRAL
ACTIVITY OF HUMAN LEUKOCYTE INTERFERON.

L9 ANSWER 50 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI ULTRASTRUCTURAL IDENTIFICATION OF VIRUS IN HUMAN CENTRAL NERVOUS SYSTEM
DISEASE.

L9 ANSWER 51 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI CAUSES OF THE DEATH OF WILD UNGULATES IN THE CENTRAL DNIEPER REGION
RUSSIAN-SFSR USSR.

L9 ANSWER 52 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI THE DETECTION OF TRANSMISSIBLE GASTROENTERITIS VIRAL ANTIBODIES BY IMMUNO
DIFFUSION.

L9 ANSWER 53 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI VIRAL IMMUNO DIAGNOSIS.

L9 ANSWER 54 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI VIRAL ENCEPHALITIS A CLINICAL ELECTRO ENCEPHALOGRAPHIC VIROLOGICAL AND
PATHOLOGICAL STUDY IN 32 CASES.

L9 ANSWER 55 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI COMPARATIVE STUDY OF THE PROTEIN KINASE ASSOCIATED WITH ANIMAL VIRUSES.

L9 ANSWER 56 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI CHANGES IN CENTRAL NERVOUS SYSTEM NEURONS IN WHITE MICE UNDER THE
INFLUENCE OF SOME NEUROTROPIC VIRUSES.

L9 ANSWER 57 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI INHIBITORS AGAINST **RABIES** VIRUS PRESENT IN NORMAL RABBIT SERA.

L9 ANSWER 58 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI ZOONOSES OF LABORATORY ANIMALS VIRAL AND RICKETTSIAL.

L9 ANSWER 59 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI IMMUNO PATHOLOGY DURING VIRAL INFECTIONS.

L9 ANSWER 60 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI SOME FORMS OF VIRAL ZOONOSIS.

L9 ANSWER 61 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI ISOPRINOSINE LACK OF ANTI VIRAL ACTIVITY IN EXPERIMENTAL MODEL INFECTIONS.

L9 ANSWER 62 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI A COORDINATED STUDY OF THE ANTI VIRAL SUBSTANCE PROGRAM.

L9 ANSWER 63 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI IMMUNO SUPPRESSION AND EXPERIMENTAL VIRUS INFECTION OF THE NERVOUS SYSTEM.

L9 ANSWER 64 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
TI DIAGNOSTIC PROCEDURES FOR VIRAL AND RICKETTSIAL INFECTIONS.

=> d 19 29

L9 ANSWER 29 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1993:478535 BIOSIS
DN PREV199396112135
TI Resistance of mice vaccinated with **rabies** virus internal
structural proteins to lethal infection.
AU Takita-Sonoda, Y.; Fujii, H.; Mifume, K. [Reprint author]; Ito, Y.;
Hiraga, M.; Nishizono, A.; Mannen, K.; Minamoto, N.
CS Dep. Microbiol., Oita Med. Univ., Hasama-machi, Oita 879-55, Japan
SO Archives of Virology, (1993) Vol. 132, No. 1-2, pp. 51-65.
CODEN: ARVIDF. ISSN: 0304-8608.
DT Article
LA English
ED Entered STN: 22 Oct 1993
Last Updated on STN: 22 Oct 1993

=> d 19 29 ab

L9 ANSWER 29 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AB Mice were vaccinated with recombinant vaccinia virus (rVac) expressing the
glycoprotein (G), nucleoprotein (N), phosphoprotein (NS) or matrix protein
(M) of **rabies** virus and their resistance to peripheral lethal
infection with street **rabies** virus was examined. Mice
vaccinated with rVac-G or rVac-N developed strong antibody responses to
the corresponding proteins and essentially all mice survived challenge
infection. Mice vaccinated with rVac-NS or rVac-M developed only a slight
antibody response, however, a significant protection (59%) was observed in
the rVac-NS-vaccinated mice, whereas rVac-M-vaccinated mice were not
protected. No anti-G antibodies were detected in the sera of mice which
had been vaccinated with rVac-N or rVac-NS and survived challenge
infection. Passive transfer of anti-N monoclonal antibodies (MAbs)
recognizing an epitope located on amino acids 1-224 of the protein prior
to challenge resulted in significant protection, although the protection
was not complete even with a high amount of antibodies. In contrast, none
of the mice given MAbs recognizing an epitope of amino acids 247-415 or
F(ab')-2 fragments from a protective MAb IgG were protected.
Administration of anti-CD8 MAb to rVac-N-vaccinated mice showed no
significant effect on protection. Our observations suggest that a
considerable part of the protection achieved by the vaccination with
rVac-N can be ascribed to the intact anti-N antibodies recognizing an
epitope located on amino acids 1-224 of the protein.

=> d his

(FILE 'HOME' ENTERED AT 10:39:13 ON 17 MAY 2005)

FILE 'MEDLINE' ENTERED AT 10:39:23 ON 17 MAY 2005

L1 49 S RABIES AND HERPESVIRUS
L2 19817 S CROSS REACTIV?
L3 0 S L1 AND L2
L4 802 S CROSS PROTECTION
L5 0 S L1 AND L4
L6 9 S L4 AND RABIES

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 10:47:35 ON 17 MAY 2005
SEA L1 AND L4

1 FILE AGRICOLA
13 FILE USPATFULL
1 FILE USPAT2
1 FILE VETU
L7 QUE L1 AND L4

FILE 'USPATFULL' ENTERED AT 10:50:46 ON 17 MAY 2005

L8 13 S L1 AND L4

FILE 'BIOSIS' ENTERED AT 10:52:50 ON 17 MAY 2005

L9 64 S L1

=> d 18 1-13

L8 ANSWER 1 OF 13 USPATFULL on STN
AN 2005:62587 USPATFULL
TI Anti-coronavirus vaccine
IN Aubert, Andre, Antibes, FRANCE
Duquesne, Veronique, Carros, FRANCE
Eloit, Marc, Saint-Maur, FRANCE
Gonon, Valerie, Le Perray en Yvelines, FRANCE
PI US 2005053622 A1 20050310
AI US 2004-485258 A1 20040810 (10)
WO 2002-FR2843 20020809
PRAI FR 2001-10644 20010809
DT Utility
FS APPLICATION
LN.CNT 1420
INCL INCLM: 424/204.100
INCLS: 530/350.000
NCL NCLM: 424/204.100
NCLS: 530/350.000
IC [7]
ICM: A61K039-12
ICS: C07K014-005
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 13 USPATFULL on STN
AN 2004:150989 USPATFULL
TI Immunogenic complex comprising ribosomes
IN Timmerman, Benedikt, Toulouse, FRANCE
PI US 2004115210 A1 20040617
AI US 2003-250664 A1 20030707 (10)
WO 2002-IB739 20020104
PRAI GB 2001-757 20010106
DT Utility
FS APPLICATION
LN.CNT 2428
INCL INCLM: 424/184.100
NCL NCLM: 424/184.100
IC [7]
ICM: A61K039-00
ICS: A61K039-38
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 13 USPATFULL on STN
AN 2004:50422 USPATFULL
TI Vaccines for cat scratch fever
IN Chomel, Bruno B., Davis, CA, UNITED STATES
Kasten, Rickie W., Davis, CA, UNITED STATES
Yamamoto, Kazuhiro, Yao-City, JAPAN
PA REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA, 94607 (U.S. corporation)
PI US 2004037849 A1 20040226
AI US 2002-227078 A1 20020821 (10)
DT Utility
FS APPLICATION
LN.CNT 731
INCL INCLM: 424/204.100
INCLS: 435/252.100
NCL NCLM: 424/204.100
NCLS: 435/252.100
IC [7]
ICM: A61K039-12
ICS: C12N001-20

L8 ANSWER 4 OF 13 USPATFULL on STN
AN 2003:194137 USPATFULL
TI Polynucleotide vaccine formula against canine pathologies, in particular

respiratory and digestive pathologies
IN Audonnet, Jean-Christophe, Lyon, FRANCE
Bouchardon, Annabelle, Lyon, FRANCE
Riviere, Michel, Ecully, FRANCE
PI US 2003133947 A1 20030717
AI US 2002-211502 A1 20020802 (10)
RLI Continuation-in-part of Ser. No. US 2001-784982, filed on 16 Feb 2001,
PENDING Division of Ser. No. US 1999-232477, filed on 15 Jan 1999,
GRANTED, Pat. No. US 6228846 Continuation-in-part of Ser. No. WO
1997-FR1316, filed on 15 Jul 1997, UNKNOWN
PRAI FR 1996-9401 19960716
DT Utility
FS APPLICATION
LN.CNT 851
INCL INCLM: 424/199.100
INCLS: 424/204.100; 435/006.000; 435/069.100; 435/320.100
NCL NCLM: 424/199.100
NCLS: 424/204.100; 435/006.000; 435/069.100; 435/320.100
IC [7]
ICM: C12Q001-68
ICS: C12P021-06; A61K039-12; C12N015-00; C12N015-09; C12N015-63;
C12N015-70; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 13 USPATFULL on STN
AN 2003:23336 USPATFULL
TI Feline polynucleotide vaccine formula
IN Audonnet, Jean-Christophe, Lyon, FRANCE
Bouchardon, Annabelle, Lyon, FRANCE
Baudu, Philippe, Craponne, FRANCE
Riviere, Michel, Ecully, FRANCE
PI US 2003017172 A1 20030123
AI US 2001-943443 A1 20010830 (9)
RLI Division of Ser. No. US 1999-232278, filed on 15 Jan 1999, PATENTED
Continuation-in-part of Ser. No. WO 1997-FR1315, filed on 15 Jul 1997,
UNKNOWN
PRAI FR 1996-9337 19960719
DT Utility
FS APPLICATION
LN.CNT 2714
INCL INCLM: 424/202.100
INCLS: 424/093.200; 435/320.100; 424/224.100
NCL NCLM: 424/202.100
NCLS: 424/093.200; 435/320.100; 424/224.100
IC [7]
ICM: A61K048-00
ICS: A61K039-295; A61K039-205; C12N015-86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 13 USPATFULL on STN
AN 2002:122824 USPATFULL
TI Oral immunization with transgenic plants
IN Arntzen, Charles J., Ithaca, NY, United States
Mason, Hugh S., Ithaca, NY, United States
Tariq, Haq A., San Antonio, TX, United States
Clements, John D., New Orleans, LA, United States
PA The Texas A&M University System, College Station, TX, United States
(U.S. corporation)
The Administrators of the Tulane Fund, New Orleans, LA, United States
(U.S. corporation)
PI US 6395964 B1 20020528
WO 9612801 19960502
AI US 1997-817906 19970804 (8)
WO 1995-US13376 19951024
19970804 PCT 371 date
DT Utility
FS GRANTED
LN.CNT 2920

INCL INCLM: 800/288.000
INCLS: 424/186.100; 424/257.100; 424/261.100; 435/069.300; 435/320.100;
435/419.000; 435/468.000; 800/287.000; 800/298.000
NCL NCLM: 800/288.000
NCLS: 424/186.100; 424/257.100; 424/261.100; 435/069.300; 435/320.100;
435/419.000; 435/468.000; 800/287.000; 800/298.000
IC [7]
ICM: C12N005-04
ICS: C12N015-82; C12N015-87; A01H005-00
EXF 800/278; 800/287; 800/288; 800/295; 800/298; 800/FOR101; 800/FOR102;
424/184.1; 424/185.1; 424/190.1; 424/192.1; 424/197.11; 424/236.1;
424/241.1; 424/257.1; 424/186.1; 424/261.1; 435/69.3; 435/410; 435/419;
435/320.1; 435/468; 536/23.1; 536/23.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 13 USPATFULL on STN
AN 2002:34189 USPATFULL
TI Feline polynucleotide vaccine formula
IN Audonnet, Jean-Christophe, Lyons, FRANCE
Bouchardon, Annabelle, Lyons, FRANCE
Baudu, Philippe, Craponne, FRANCE
Riviere, Michel, Ecully, FRANCE
PA Merial, Lyons, FRANCE (non-U.S. corporation)
PI US 6348196 B1 20020219
AI US 1999-232278 19990115 (9)
RLI Continuation-in-part of Ser. No. WO 1997-FR1315, filed on 15 Jul 1997
PRAI FR 1996-9337 19960719
DT Utility
FS GRANTED
LN.CNT 939
INCL INCLM: 424/202.100
INCLS: 424/204.100; 424/221.100; 435/320.100; 514/044.000
NCL NCLM: 424/202.100
NCLS: 424/204.100; 424/221.100; 435/320.100; 514/044.000
IC [7]
ICM: A61K039-295
EXF 435/320.1; 514/44; 424/202.1; 424/204.1; 424/207.1; 424/208.1; 424/221.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 13 USPATFULL on STN
AN 2001:119336 USPATFULL
TI Polynucleotide vaccine formula against canine pathologies, in particular
respiratory and digestive pathologies
IN Audonnet, Jean-Christophe, Lyon, France
Bouchardon, Annabelle, Lyon, France
Riviere, Michel, Ecully, France
PI US 2001009959 A1 20010726
US 6586412 B2 20030701
AI US 2001-784982 A1 20010216 (9)
RLI Division of Ser. No. US 1999-232477, filed on 15 Jan 1999, GRANTED, Pat.
No. US 6228846 Continuation-in-part of Ser. No. WO 1997-FR1316, filed on
15 Jul 1997, UNKNOWN
PRAI FR 1996-9401 19960719
DT Utility
FS APPLICATION
LN.CNT 661
INCL INCLM: 536/023.700
INCLS: 514/044.000; 435/320.100; 424/186.100; 424/190.100; 424/201.100;
424/224.100; 424/229.100; 424/231.100; 424/248.100; 536/023.100;
536/023.720; 435/069.100; 435/455.000; 435/466.000; 435/476.000
NCL NCLM: 514/044.000
NCLS: 435/320.100; 536/023.700; 536/023.720
IC [7]
ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 13 USPATFULL on STN
AN 2001:67657 USPATFULL